Long-Term Real-World Evidence of Clinical Suppression with 6-Month Subcutaneous Leuprolide Acetate in Children with Central Precocious Puberty (ENDO 2026) - Jun 2, 2026 - Abstract #SAT-228; Pres time: Jun 13, 2026; 09:30 AM - 04:30 PM; Location: ENDOExpo; Poster Floor; "SC-LA demonstrated sustained clinical suppression, including suppression of HV to the prepubertal range and stabilization of pubertal progression as reflected by maintained or regressed Tanner stage. These findings complement and extend the phase 3 pivotal trial results by providing supportive long-term real-world evidence for the effectiveness of SC-LA in children treated for CPP."
Clinical • HEOR • Real-world • Real-world evidence • Endocrine Disorders
|
|
Naznin Dixit, MD, DM; Middey Damian, MD; Lena Yoo, PharmD; Deborah Boldt-Houle, PhD
|